Anakinra long-term efficacy and safety in the management of Schnitzler's syndrome and latent tuberculosis infection

Clinical and Experimental Rheumatology

Volumn 34, Issue 2, 2016, Pages 353-353

  Lopalco, G ^a   Vitale, A ^b   Iannone, F ^a   Cantarini, Luca ^b  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; METHOTREXATE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ANTIRHEUMATIC AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; CASE REPORT; CLINICAL FEATURE; COMORBIDITY; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; HEMOLYTIC ANEMIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LATENT TUBERCULOSIS; LETTER; LONG TERM CARE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS TEST KIT; PRIORITY JOURNAL; SCHNITZLER SYNDROME; SKIN BIOPSY; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; MALE; OPPORTUNISTIC INFECTION; PYOMYOSITIS; TUBERCULOSIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; OPPORTUNISTIC INFECTIONS; PYOMYOSITIS; TUBERCULOSIS;

EID: 84963853284     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Letter

References (11)

1. MIGKOS MP, SOMARAKIS GA, MARKATSELI TE et al.: Tuberculous pyomyositis in a rheumatoid arthritis patient treated with anakinra. Clin Exp Rheumatol 2015; 33: 734-6
2. SIMON A, ASLI B, BRAUN-FALCO M et al.: Schnitzler's syndrome: diagnosis, treatment, and followup. Allergy 2013; 68: 562-8
3. DYE C, WATT CJ, BLEED DM, HOSSEINI SM, RAVIGLIONE MC: Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 2005; 293: 2767-75
4. ZUñIGA J, TORRES-GARCíA D, SANTOS-MENDOZA T, RODRIGUEZ-REYNA TS, GRANADOS J, YUNIS EJ: Cellular and humoral mechanisms involved in the control of tuberculosis. Clin Dev Immunol 2012; 2012: 193923
5. GULER R, PARIHAR SP, SPOHN G, JOHANSEN P, BROMBACHER F, BACHMANN MF: Blocking IL-1a but not IL-1ß increases susceptibility to chronic Mycobacterium tuberculosis infection in mice. Vaccine 2011; 29: 1339-46
6. LOPALCO G, CANTARINI L, VITALE A et al.: Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. Mediators Inflamm 2015; 2015: 194864
7. NéEL A, HENRY B, BARBAROT S et al.: Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: a French multicenter study. Autoimmun Rev 2014; 13: 1035-41
8. EMMI G, TALARICO R, LOPALCO G et al.: Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study. Clin Rheumatol 2015 July 10 [Epub ahead of print]
9. CANTARINI L, VITALE A, SCALINI P et al.: Anakinra treatment in drug-resistant Behçet's disease: a case series. Clin Rheumatol 2015; 34: 1293-301
10. CANTARINI L, TALARICO R, GENERALI E et al.: Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study. Int J Rheum Dis 2015 August 18 [Epub ahead of print]
11. CANTARINI L, LOPALCO G, CASO F et al.: Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease. Autoimmun Rev 2015; 14: 1-9